Aposense wins NIH funding for brain tumor trial

Aposense signed a collaboration deal with the University of Pittsburgh in which the university will have the right to use the company's technology for researching GBM tumor patients.

Aposense Ltd. (TASE: APOS) today reported that it is starting an additional clinical trial with funding from the US government's National Institutes of Health (NIH), using its EarliTest technology to detect GBM brain tumors.

Aposense (formerly NST) is a clinical stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo.

Aposense signed a collaboration agreement with the University of Pittsburgh in which the university will have the right to use the company's technology for researching GBM tumor patients, the most common form of tumors. The research will be funded by NIH.

The University of Pittsburgh is planning a clinical trial that will examine the effectiveness of EarliTest and Aposense's ML-10 marker and evaluate the effectiveness of treatment in the early stages of the illness. Simulating the effectiveness of treating this type of cancer is one of the most difficult. MRI is the most sensitive method for this purpose, and errs in 50% of cases where treatment fails.

Clinical data gathered by the EarliTest system during the trial will assist Aposense in gaining approval from the US Food and Drug Administration (FDA).

Published by Globes, Israel business news - www.globes-online.com - on March 27, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018